TherVacB – A THERAPEUTIC VACCINE TO CURE HEPATITIS B
European Commission and TherVacB join forces
The role of viral hepatitis as a public health threat has long been underestimated. Only very recently, the United Nations in their “2030 Agenda for Sustainable Development” called for international action to combat viral hepatitis and reduce the disease burden. The major killer is the hepatitis B virus (HBV) causing liver cirrhosis and liver cancer. Worldwide 880,000 humans die each year from the consequences of an HBV infection.
A prophylactic vaccine is available to prevent HBV infection, but more than 3% of the world’s population (about 260 million humans) are chronically infected and do not profit from that vaccine anymore. For those suffering from chronic hepatitis B, until today no curative treatment option exists.
The European Commission therefore selected the project TherVacB led by Helmholtz Zentrum München for a five-year funding within the Horizon 2020 program.
A consortium of leading virologists, immunologists and physicians specialized in treating viral hepatitis, will use a newly designed therapeutic vaccine, TherVacB, as an immunotherapy to cure HBV. TherVacB will be evaluated in a three-year clinical trial starting in 2022 conducted in Europe and in Africa. Integration of a partner site in Tanzania shall help building local capacities for diagnosing and treating hepatitis B and support an important goal of the consortium – to raise awareness for hepatitis B.
About TherVacB
For Patients
TherVacB Team
Partners
European countries
Project duration (months)
European Testing Week, 22-29 November 2021
Get your one-off screening for hepatitis B from your GP in Germany Hepatitis B can be treated well at an early stage, hepatitis C can even be cured. In Germany, like in other countries and regions of the world, many people affected are unaware of their infection....
HBV Cure Research Community Webinar, 24th November 2021
An online discussion for the HBV community on scientific progress in Europe towards a cure features the European HBV Patient Registry. The International Coalition for the Elimination of HBV, ICE-HBV, in partnership with Liver Patients International open the...
Telefonsprechstunde zur Hepatitis B am 16.11.2021
Haben Sie Fragen zur Virushepatitis? Sprechen Sie im Rahmen einer speziellen Telefonsprechstunde zur Hepatitis B direkt mit Prof. Dr. Markus Cornberg, Erstautor der aktuellen Leitlinie zur Hepatitis B und Oberarzt an der Medizinischen Hochschule Hannover, einem der...
Animation movie
Enjoy our animation movie to understand the mission and approach of the TherVacB project!
;
@EU_Health Excellent start of the year congratulations 👏👏👏 we hope that soon we will have screening program for one of the most preventable cancers
▶️#LiverCancer
👉#Elimination #Hepatitis C,
👉Reduction #Hepatitis B
👉#Alcohol
👉#obesity
👉#NAFLD
👉#NASH
#lifestyle #EUCancerPlan
The best way to deal with quality issues is to prevent them from occurring in the first place. To achieve this goal, the #ISO9001 Standard implies the identification and control of potential risks.
#WednesdayWisdom #HumpDay
@asscatinforma @fneth_org @EU_Health @EASLnews @WHO
ELPA is proud to 📢 inform you that we are part of a network with over 3️⃣5️⃣ eligible organisations, ensuring that the needs and concerns of a wide range of #liverpatients and consumers are represented via direct contact with the @EMA_News @EU_Health
https://www.ema.europa.eu/en/partners-networks/patients-consumers/eligible-patients-consumers-organisations?s=07
If you personally experienced #discrimination due to #hepatitisB, you can report discrimination at the Hepatitis B Foundation's Discrimination Registry here: http://www.surveymonkey.com/r/hepbdiscrimination
It is anonymous and will help to document how serious this problem is.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848223.